Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most ...

Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and ...